Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: what Amgen’s $3.7bn ChemoCentryx buy means; Lilly’s CEO on US drug pricing legislation; Pfizer’s GBT acquisition; new data for Amgen’s KRAS inhibitor combo; and a major China ADC alliance for Sanofi.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 12 August 2022, including: what Amgen, Inc.’s $3.7bn ChemoCentryx, Inc. buy means; Eli Lilly and Company’s CEO on US drug pricing legislation; Pfizer Inc.’s Global Blood Therapeutics, Inc. acquisition; new data for Amgen’s KRAS inhibitor combo; and a major China ADC alliance for Sanofi.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Amgen’s $3.7bn ChemoCentryx Buy May Help Offset Growing Pains" - Scrip, 4 Aug, 2022.)
(Also see "As Lilly’s Realized Sales Prices Drop, Ricks Reiterates Criticism Of US Drug Price Plan" - Scrip, 4 Aug, 2022.)
(Also see "Pfizer’s Buying Spree Continues With GBT, Gaining A Sickle Cell Disease Franchise" - Scrip, 8 Aug, 2022.)
(Also see "Can Amgen Balance Efficacy, Safety With KRAS/PD-1 Combination?" - Scrip, 8 Aug, 2022.)
(Also see "Sanofi, Innovent Link On China Oncology Ambitions As ADCs Surge" - Scrip, 5 Aug, 2022.)